The significance of low-level plasma HIV viral load on COBAS TaqMan® HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor® monitor version 1.5

HIV Clinical Trials

Volumn 9, Issue 4, 2008, Pages 283-286

  Manavi, Kaveh ^a  

^a SELLY OAK HOSPITAL   (United Kingdom)

Author keywords

Amplicor ; Clinical outcome; Discordant; TaqMan assay; Viral load assays

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE; VIRAL LOAD;

EID: 51749121954     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0904-283     Document Type: Article

References (11)

1. Perrin L, Pawlotsky JM, Bouvier-Alias M, Sarrazin C, Zeuzem S, Colucci G. Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol. 2006;44:4371-4375.
2. Damond F, Roquebert B, Bénard A, et al. Human immunodeficiency virus Type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 Monitor Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assays. J Clin Microbiol. 2007;45:3436-3438.
3. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
4. García-Gascó P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61:699-704.
5. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS. 2002;16:615-618.
6. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
7. Schumacher W, Frick E, Kauselmann M, Maier-Hoyle V, van der Vliet R, Babiel R. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan® system. J Clin Virol. 2007;38:304-312.
8. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007;196:1773-1778.
9. Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001; 28:105-113.
10. Macias J, Palomares JC, Mira A et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51:195-200.
11. Mira A Macías J, Nogales C, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther. 2002; 7:251-256.